Livzon Pharma Releases 2025 Annual Report and AGM Documentation Online

Bulletin Express04-23

On 23 April 2026, Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that the following corporate documents are now available on both the company website (www.livzon.com.cn) and the Hong Kong Stock Exchange’s website (www.hkexnews.hk):

• 2025 Annual Report • Circular dated 23 April 2026 • Notice and Proxy Form for the 2025 Annual General Meeting • Notice and Proxy Form for the 2026 First Class Meeting of H-Shareholders

The board recommends shareholders and investors review the digital versions to ensure timely access to information. Non-registered holders experiencing difficulty with electronic access may obtain printed copies free of charge by completing the enclosed request form and sending it to the Hong Kong branch share registrar, Tricor Investor Services Ltd., at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, or by emailing 1513-ecom@vistra.com.

Stakeholders wishing to switch to electronic delivery must provide a functional email address through their respective banks, brokers, custodians, nominees, or HKSCC Nominees Ltd. Until a valid email address is registered, non-registered holders will continue to receive hard-copy notices of publication.

Enquiries can be directed to Tricor Investor Services’ hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m. to 6:00 p.m. (excluding public holidays).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment